Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Halozyme Therapeutics

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?

HALO or FOLD: Which Is the Better Value Stock Right Now?

Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al.

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

Immuneering Corp

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors?

HALO vs. FOLD: Which Stock Is the Better Value Option?

Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Saul Ortega & David Rogers v. Office of the Comptroller of the Currency Saul Ortega & David Rogers v. Office of the Comptroller of the Currency

NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights

FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.

Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

Clipper Realty

Harrow Health Inc

FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.

Best Momentum Stocks to Buy for October 24th

Blueprint Medicines

CRISPR Therapeutics

Exelixis

Verona Pharma

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

GitLab

Trip.com

CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.

New Strong Buy Stocks for October 24th

WASHINGTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- American Citizens Abroad (ACA) has joined parties opposing actions which would narrow the ability of U.S. citizens living overseas to vote. In Pennsylvania, steps have been taken by state officials to make it easier for voters overseas to vote. Plaintiffs in the lawsuit would narrow voter registration rules as they apply to U.S. citizens living overseas.

American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas

Merck

Teva Pharmaceutical

SPDR S&P Biotech ETF

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.

News for Amicus Therapeutics Stock (FOLD)